logo

Proliferative Diabetic Retinopathy Market Size (2024 - 2029)

The proliferative diabetic retinopathy market is anticipated to experience significant growth, driven by the increasing prevalence of diabetes and the aging population. This market expansion is further supported by advancements in technology and minimally invasive laser techniques, which enhance treatment options. The condition, a severe complication of diabetes characterized by abnormal blood vessel growth in the retina, poses a risk of long-term vision loss if untreated. The market's growth trajectory is influenced by the rising incidence of diabetes, particularly in low- and middle-income countries, where healthcare resources for managing such complications are often limited.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Proliferative Diabetic Retinopathy Industry Market Size

Market Size of Proliferative Diabetic Retinopathy Industry

market snapshot grapgh
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 9.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Proliferative Diabetic Retinopathy Market Analysis

The Proliferative Diabetic Retinopathy Market is expected to register a CAGR of 9.4% during the forecast period. Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina. Some of the signs and symptoms are progressive loss of vision, fine to severe loops of new vessels that may grow on the optic disc and these new vessels may leak and resulting in retinal edema and so on. The major risk factors for proliferative diabetic retinopathy (PDR) include the duration of diabetes, for 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of proliferative diabetic retinopathy (PDR).

According to the International Agency for the Prevention of Blindness, low- and middle-income countries account for approximately 75% of the global diabetes burden, yet many people are ill-equipped to properly identify, treat and manage this disease. Furthermore, as per the study published in the Ophthalmological Journal, estimates diabetic retinopathy affects 1 in 3 people with diabetes and by the year 2040, diabetes is projected to affect 642 million adults.

Growth in the geriatric population increases the prevalence of diabetes and diabetic retinopathy and the availability of advanced technology and minimally invasive laser technique are the key driving factors in the proliferative diabetic retinopathy market.

Proliferative Diabetic Retinopathy Industry Segmentation

Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative Diabetic Retinopathy Market is segmented By Treatment Type and Geography.

By Treatment Type
Anti-VEGF Agents
Corticosteroids
Laser Surgery
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Proliferative Diabetic Retinopathy Market Size Summary

The proliferative diabetic retinopathy market is poised for significant growth, driven by the increasing prevalence of diabetes and the advancements in medical technology. Proliferative diabetic retinopathy, a severe complication of diabetes, involves the growth of new blood vessels on the retina, which can lead to vision loss if untreated. The condition is more prevalent in individuals with a long history of diabetes, and its incidence is rising, particularly in low- and middle-income countries where diabetes management is often inadequate. The geriatric population's growth further exacerbates this trend, as older adults are more susceptible to diabetes and its complications. The market is characterized by the availability of advanced technologies and minimally invasive treatments, which are crucial in managing this condition effectively.

The anti-VEGF agents segment holds a significant portion of the market share, attributed to their effectiveness in improving visual acuity in patients with proliferative diabetic retinopathy. This segment is expected to maintain its prominence due to the rising prevalence of diabetic retinopathy and the ongoing advancements in treatment options. North America is anticipated to dominate the global market, supported by a high prevalence of diabetes and well-established healthcare infrastructure. The market is consolidated, with a few major players like Novartis AG, Regeneron Pharmaceuticals Inc, and Allergan Plc leading the industry. These companies are pivotal in shaping the market dynamics through their innovative treatment solutions and strategic initiatives.

Explore More

Proliferative Diabetic Retinopathy Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Diabetes Increases Risk of Diabetic Retinopathy

      2. 1.2.2 Availability of Advanced Technology and Minimally Invasive Laser Technique

    3. 1.3 Market Restraints

      1. 1.3.1 Extended Approval Time for Drugs

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Treatment Type

      1. 2.1.1 Anti-VEGF Agents

      2. 2.1.2 Corticosteroids

      3. 2.1.3 Laser Surgery

      4. 2.1.4 Others

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Mexico

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 United Kingdom

        3. 2.2.2.3 France

        4. 2.2.2.4 Italy

        5. 2.2.2.5 Spain

        6. 2.2.2.6 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 China

        2. 2.2.3.2 Japan

        3. 2.2.3.3 India

        4. 2.2.3.4 Australia

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Rest of Asia-Pacific

      4. 2.2.4 Middle-East and Africa

        1. 2.2.4.1 GCC

        2. 2.2.4.2 South Africa

        3. 2.2.4.3 Rest of Middle-East and Africa

      5. 2.2.5 South America

        1. 2.2.5.1 Brazil

        2. 2.2.5.2 Argentina

        3. 2.2.5.3 Rest of South America

Proliferative Diabetic Retinopathy Market Size FAQs

The Proliferative Diabetic Retinopathy Market is projected to register a CAGR of 9.40% during the forecast period (2024-2029)

Novartis AG, Regeneron Pharmaceuticals Inc, Allergan Plc, Hoffmann-La Roche (Genentech) and Oxurion NV are the major companies operating in the Proliferative Diabetic Retinopathy Market.

Proliferative Diabetic Retinopathy Market Report Snapshots

Proliferative Diabetic Retinopathy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)